182 related articles for article (PubMed ID: 18426860)
1. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis.
Picha KM; Cunningham MR; Drucker DJ; Mathur A; Ort T; Scully M; Soderman A; Spinka-Doms T; Stojanovic-Susulic V; Thomas BA; O'Neil KT
Diabetes; 2008 Jul; 57(7):1926-34. PubMed ID: 18426860
[TBL] [Abstract][Full Text] [Related]
2. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.
Parlevliet ET; Schröder-van der Elst JP; Corssmit EP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H
J Pharmacol Exp Ther; 2009 Jan; 328(1):240-8. PubMed ID: 18849357
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
Baggio LL; Kim JG; Drucker DJ
Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
[TBL] [Abstract][Full Text] [Related]
4. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
5. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
6. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
Gault VA; Bhat VK; Irwin N; Flatt PR
J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
[TBL] [Abstract][Full Text] [Related]
7. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.
Maida A; Lovshin JA; Baggio LL; Drucker DJ
Endocrinology; 2008 Nov; 149(11):5670-8. PubMed ID: 18669601
[TBL] [Abstract][Full Text] [Related]
8. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Diabetes; 2004 Sep; 53(9):2492-500. PubMed ID: 15331566
[TBL] [Abstract][Full Text] [Related]
9. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Glaesner W; Vick AM; Millican R; Ellis B; Tschang SH; Tian Y; Bokvist K; Brenner M; Koester A; Porksen N; Etgen G; Bumol T
Diabetes Metab Res Rev; 2010 May; 26(4):287-96. PubMed ID: 20503261
[TBL] [Abstract][Full Text] [Related]
10. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
11. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
Bhat VK; Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
[TBL] [Abstract][Full Text] [Related]
12. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
14. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides.
Kim BJ; Zhou J; Martin B; Carlson OD; Maudsley S; Greig NH; Mattson MP; Ladenheim EE; Wustner J; Turner A; Sadeghi H; Egan JM
J Pharmacol Exp Ther; 2010 Sep; 334(3):682-92. PubMed ID: 20498254
[TBL] [Abstract][Full Text] [Related]
15. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
Werner U
J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling.
Lovshin J; Estall J; Yusta B; Brown TJ; Drucker DJ
J Biol Chem; 2001 Jun; 276(24):21489-99. PubMed ID: 11262390
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A; Carrington PE; Adams JR; Wright M; Eiermann G; Zhu L; Du X; Petrov A; Lassman ME; Jiang G; Liu F; Miller C; Tota LM; Zhou G; Zhang X; Sountis MM; Santoprete A; Capito' E; Chicchi GG; Thornberry N; Bianchi E; Pessi A; Marsh DJ; SinhaRoy R
Diabetes; 2009 Oct; 58(10):2258-66. PubMed ID: 19602537
[TBL] [Abstract][Full Text] [Related]
18. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
19. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.
Scrocchi LA; Marshall BA; Cook SM; Brubaker PL; Drucker DJ
Diabetes; 1998 Apr; 47(4):632-9. PubMed ID: 9568697
[TBL] [Abstract][Full Text] [Related]
20. Targeting the glucagon receptor family for diabetes and obesity therapy.
Cho YM; Merchant CE; Kieffer TJ
Pharmacol Ther; 2012 Sep; 135(3):247-78. PubMed ID: 22659620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
